Breast Cancer Biomarkers: The Emerging Role of Immune and Digital Biomarkers and the Benefits of Parallel CDx Development

How do you identify the right patient for a given drug? How do you select your population to ensure that the signal of benefit is most pronounced? The boundaries of breast cancer biomarker development are being increasingly pushed to help power better decisions for developers, oncologists and, ultimately, for breast cancer patients.

This webinar will explore a range of topics, including:

• Recent and emerging breast cancer biomarkers
• Platforms for breast cancer biomarker identification and characterization (such as tumor microenvironment, tumor infiltrating lymphocytes, liquid biopsies, immune and digital biomarkers)
• The translation of breast cancer biomarkers into the development of new breast cancer therapies
• The benefits of parallel development of companion diagnostics (CDx) for “day 1 readiness” in securing commercialization for new therapies.

Register for this webinar to learn about the emerging role of immune and digital biomarkers, and the benefits of parallel development of therapeutics and CDx.

Speakers

Kamal Veer Singh Saini, MBBS, MD, MRCP (UK), DM (Med Onc), Executive Medical Director, Labcorp Oncology

Kamal Veer Singh Saini, MD, is Executive Medical Director, Labcorp Oncology, based in Brussels, Belgium. Kamal is a board-certified medical oncologist, with an active license to practice in the UK. He contributes to the scientific strategic leadership of the Oncology area at Labcorp, and provides clinical and medical expertise to project teams and other Labcorp departments on clients’ drug development projects.

Kamal brings more than 15 years of experience in clinical research and development. He previously served as Associate Scientific Director for an academic research organization and as Medical Advisor, for the Institute Jules Bordet, Brussels. The author or co-author of several peer-reviewed journal articles, Kamal joined Labcorp in June 2015.

Message Presenter

Maria J. Prendes, PhD, MS, Head of Oncology Biomarker Solution Center, Labcorp Oncology

Dr. Maria Prendes leads the Biomarker Solution Center oncology therapeutic team and works with clients to guide the selection, characterization and development of biomarkers for their clinical trials. Her responsibilities also include supporting companion diagnostics (CDx) development efforts.

Specializing in the fields of immuno-oncology, cancer genetics, cancer biology and molecular oncology, Dr. Prendes has more than 15 years of experience in drug development where she directed research for the identification of new clinical biomarkers in oncology as well as designed, developed and characterized antibodies against specific biomarker targets to be used as therapeutic agents and for development of CDx assays. She is the holder of multiple US patents and has authored and co-authored numerous journal articles.

Message Presenter